Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;2(3):263-83.
doi: 10.1007/s12072-008-9080-3. Epub 2008 May 10.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Yun-Fan Liaw  1 , Nancy Leung, Jia-Horng Kao, Teerha Piratvisuth, Edward Gane, Kwang-Hyub Han, Richard Guan, George K K Lau, Stephen Locarnini; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Affiliations

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Yun-Fan Liaw et al. Hepatol Int. 2008 Sep.

Erratum in

  • Errata.
    Omata M, Sarin SK. Omata M, et al. Hepatol Int. 2008 Sep;2(3):395-6. doi: 10.1007/s12072-008-9089-7. Hepatol Int. 2008. PMID: 19669272 Free PMC article. No abstract available.

Abstract

Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon alpha2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Algorithm for the management of hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B infection. AFP: alphafetoprotein; ALT: alanine aminotransferase; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ULN: upper limit of normal; LT: liver transplantation
Fig. 2
Fig. 2
Algorithm for the management of hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B infection. AFP: alphafetoprotein; ALT: alanine aminotransferase; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ULN: upper limit of normal
Fig. 3
Fig. 3
Algorithm for the management of chronic hepatitis B infection with liver cirrhosis. ADV: adefovir; AFP: alphafetoprotein; ALT: alanine aminotransferase; ETV: entecavir; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; IFN: interferon; LAM: lamivudine; Ldt: telbivudine
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1478-3231.2005.01134.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1478-3231.2005.01134.x'}, {'type': 'PubMed', 'value': '15910483', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15910483/'}]}
    2. Liaw YF, Leung N, Guan R, Lau GKK, Merican I, McCaughan G et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–489. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.cgh.2006.05.016', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.cgh.2006.05.016'}, {'type': 'PubMed', 'value': '16844425', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16844425/'}]}
    2. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936–962. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1478-3231.2006.01374.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1478-3231.2006.01374.x'}]}
    2. ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int 2006;26:47–58.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/hep.21513', 'is_inner': False, 'url': 'https://doi.org/10.1002/hep.21513'}, {'type': 'PubMed', 'value': '17256718', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17256718/'}]}
    2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–539. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/0092-8674(82)90157-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/0092-8674(82)90157-x'}, {'type': 'PubMed', 'value': '6180831', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/6180831/'}]}
    2. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403–415. - PubMed

LinkOut - more resources